Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | DHODH | Q02127 | 2/20 | 0.51 |
| ▸ | METAP2 | P50579 | 1/20 | 0.51 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | EIF4E | P06730 | 3/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.48 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.48 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.48 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.48 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.48 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.48 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490357 | 0.91 | DHODH (0.60) | HSD17B10NPC1RAB9ADHODHSMN1; SMN2 | |
| SCHEMBL6495696 | 0.89 | HSD17B10 (0.58) | HSD17B10DHODHSMN1; SMN2CSNK2A1EIF4E | |
| SCHEMBL6498907 | 0.87 | ALDH1A1 (0.61) | HSD17B10NPC1RAB9ASMN1; SMN2AURKA | |
| SCHEMBL6489883 | 0.86 | NPC1 (0.51) | HSD17B10NPC1RAB9ADHODHMETAP2 | |
| SCHEMBL3733709 | 0.84 | HDAC7 (0.60) | HSD17B10DHODHMETAP2SMN1; SMN2CSNK2A1 | |
| SCHEMBL7245003 | 0.83 | PRKAB2 (0.50) | HSD17B10DHODHSMN1; SMN2CSNK2A1EIF4E | |
| SCHEMBL27999421 | 0.83 | HSD17B10 (0.51) | HSD17B10NPC1RAB9ASMN1; SMN2CSNK2A1 | |
| SCHEMBL6492370 | 0.83 | HSD17B10 (0.51) | HSD17B10NPC1RAB9ADHODHSMN1; SMN2 | |
| SCHEMBL2561925 | 0.81 | HSD17B1 (0.53) | HSD17B10NPC1RAB9ASMN1; SMN2CSNK2A1 | |
| SCHEMBL4621112 | 0.81 | CSNK2A1 (0.65) | HSD17B10METAP2SMN1; SMN2CSNK2A1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | HSD17B10 901/4885NPC1 100/4885RAB9A 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.